arthritis

View All

Rheumatoid Arthritis Key Trends and Emerging Therapies
Which Key Player Holds the Potential to Corner the Rheumatoid Arthritis Therapeutics Market?

Rheumatoid Arthritis (RA) is a chronic, inflammatory autoimmune disease that leads to progressive and destructive polyarthritis and affects approximately 1% of the population. It is characterized by chronic pain and joint destruction that usually progress from distal to more proximal joints.  DelveInsight ...

Find More

Pharma News for Novartis and Gilead
Novartis’ Canakinumab for NSCLC; Novartis’s Zolgensma Updates; Trodelvy Prospects in New Breast Cancer Use; Novartis Secures European Approval For Pluvicto; Bristol-Myers Squibb’s Abecma Phase III Trials; Trastuzumab Approved for Deruxtecan for HER2-Mutant NSCLC

Novartis’ Canakinumab Fails in Phase III Trials for NSCLC Canakinumab's prospects as an anticancer therapy were already dwindling when a third phase III trial in non-small cell lung cancer (NSCLC) failed to reach its objectives. The most recent setback came from the CANOPY-A study, which included patients with N...

Find More

Bioelectronic Medicine
Bioelectronic Medicine: Applications and Future Prospects

Healthcare industry during the past few decades has witnessed phenomenal growth and improvement due to technological advancement and innovation. The hospital management, medical devices & equipment, pharmaceutical products, and surgical procedures all have gone under tremendous up-gradation and improvement.&nbs...

Find More

Cardiovascular Disease
Cardiovascular Disease: A major cause of health loss and a global burden

Cardiovascular diseases (CVDs) are one of the leading causes of death and health loss in people in the US. As per a study by the National Vital Statistics Report, every 37 seconds, one person dies of Cardiovascular diseases in the US.  Cardiovascular diseases also known as heart disease, encompasses a wide range...

Find More

Delveinsight
Outset Medical captures; Wright Medical Group to takeover Cartiva; Y-mAbs Therapeutics prepares for IPO; Biotech boom remunerates analysts

For all-in-one dialysis system, Outset Medical captures USD 132 Million to extend U.S. expansion Outset Medical bagged USD132 Million in series D capital. This ensued in encouraging the production capabilities and accelerating the commercial expansion for all-in-one dialysis system. The FDA cleared the Tablo Hemodia...

Find More